Apr 14, 2021 13:49 JST

Source: Eisai

Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting

TOKYO, Apr 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401), its dual orexin receptor antagonist lemborexant (product name: Dayvigo) and its antiepileptic drug perampanel (product name: Fycompa), at the Virtual American Academy of Neurology (AAN 2021) Annual Meeting from April 17 to 22, 2021.

As major presentations, an oral presentation regarding lecanemab will be given on the preliminary analysis for results of changes in brain-A beta levels and amyloid-related imaging abnormalities-edema (ARIA-E) as observed in subjects of the ongoing open-label extension of the Phase II study (Study 201) for early Alzheimer's disease (AD) patients. Poster presentations regarding lemborexant are also planned, including the results of a pilot study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment. Additionally, for perampanel, a global pooled analysis results from the real-world experiences including early adjunctive use or monotherapy will be presented at poster sessions.

Eisai considers neurology a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with the disease and their families.

For more information, visit https://www.eisai.com/news/2021/news202127.html.

Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
June 02 2025 16:46 JST
 
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28 2025 16:45 JST
 
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 21 2025 14:00 JST
 
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
May 16 2025 16:21 JST
 
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
April 30 2025 13:17 JST
 
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
April 18 2025 15:52 JST
 
Eisai to Divest Rights for Pariet in China to Peak Pharma
April 01 2025 12:15 JST
 
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
March 25 2025 16:28 JST
 
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
March 25 2025 11:21 JST
 
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
March 10 2025 19:24 JST
 
More Press release >>

Latest Press Release


More Latest Release >>